{"nctId":"NCT00400153","briefTitle":"RespimatÂ® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2006-11"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":1480,"armGroups":[{"label":"COMBIVENT Respimat 20/100 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: Combivent Respimat (20 mcg/100 mcg)","Drug: Placebo via corresponding inhaler for blinding purposes"]},{"label":"COMBIVENT CFC-MDI 36/206 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: COMBIVENT MDI (36/206 mcg)","Drug: Placebo via corresponding inhaler for blinding purposes"]},{"label":"Ipratropium Respimat 20 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: Atrovent Respimat (20 mcg)","Drug: Placebo via corresponding inhaler for blinding purposes"]}],"interventions":[{"name":"Atrovent Respimat (20 mcg)","otherNames":[]},{"name":"COMBIVENT MDI (36/206 mcg)","otherNames":[]},{"name":"Combivent Respimat (20 mcg/100 mcg)","otherNames":[]},{"name":"Placebo via corresponding inhaler for blinding purposes","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nOutpatients of either sex, 40 years or older, with a diagnosis of COPD (FEV1 65% predicted normal and FEV1/FVC 70%).\n\nExclusion Criteria:\n\nPatients with significant diseases other than COPD that may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study, with a history of asthma or allergic rhinitis, who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy or using oral corticosteroid me dication at unstable doses (i.e., less than 6 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day will be excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 AUC0-6 at Day 85","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.145","spread":"0.007"},{"groupId":"OG001","value":"0.149","spread":"0.007"},{"groupId":"OG002","value":"0.119","spread":"0.007"}]}]}]},{"type":"PRIMARY","title":"FEV1 AUC0-4 at Day 85","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.189","spread":"0.007"},{"groupId":"OG001","value":"0.190","spread":"0.007"},{"groupId":"OG002","value":"0.142","spread":"0.007"}]}]}]},{"type":"PRIMARY","title":"FEV1 AUC4-6 at Day 85","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.056","spread":"0.008"},{"groupId":"OG001","value":"0.066","spread":"0.008"},{"groupId":"OG002","value":"0.073","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-6 at Day 1","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.173","spread":"0.008"},{"groupId":"OG001","value":"0.189","spread":"0.008"},{"groupId":"OG002","value":"0.124","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-6 at Day 29","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.154","spread":"0.007"},{"groupId":"OG001","value":"0.161","spread":"0.007"},{"groupId":"OG002","value":"0.127","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-6 at Day 57","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.146","spread":"0.007"},{"groupId":"OG001","value":"0.16","spread":"0.007"},{"groupId":"OG002","value":"0.118","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-4 at Day 1","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.211","spread":"0.008"},{"groupId":"OG001","value":"0.227","spread":"0.008"},{"groupId":"OG002","value":"0.149","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-4 at Day 29","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.197","spread":"0.008"},{"groupId":"OG001","value":"0.198","spread":"0.008"},{"groupId":"OG002","value":"0.153","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC0-4 at Day 57","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.188","spread":"0.007"},{"groupId":"OG001","value":"0.200","spread":"0.007"},{"groupId":"OG002","value":"0.141","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC4-6 at Day 1","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.008"},{"groupId":"OG001","value":"0.115","spread":"0.009"},{"groupId":"OG002","value":"0.074","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC4-6 at Day 29","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.068","spread":"0.008"},{"groupId":"OG001","value":"0.087","spread":"0.008"},{"groupId":"OG002","value":"0.078","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC4-6 at Day 57","description":"Area between the test-day baseline FEV1 and the FEV1 change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.063","spread":"0.008"},{"groupId":"OG001","value":"0.084","spread":"0.008"},{"groupId":"OG002","value":"0.073","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 1","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"0.008"},{"groupId":"OG001","value":"0.323","spread":"0.008"},{"groupId":"OG002","value":"0.237","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 29","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"0.008"},{"groupId":"OG001","value":"0.296","spread":"0.008"},{"groupId":"OG002","value":"0.237","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 57","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":"0.008"},{"groupId":"OG001","value":"0.296","spread":"0.008"},{"groupId":"OG002","value":"0.223","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 85","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.293","spread":"0.008"},{"groupId":"OG001","value":"0.290","spread":"0.008"},{"groupId":"OG002","value":"0.225","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 1","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"0.008"},{"groupId":"OG001","value":"0.323","spread":"0.008"},{"groupId":"OG002","value":"0.237","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 29","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"0.008"},{"groupId":"OG001","value":"0.296","spread":"0.008"},{"groupId":"OG002","value":"0.237","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 57","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":"0.008"},{"groupId":"OG001","value":"0.296","spread":"0.008"},{"groupId":"OG002","value":"0.223","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 Response at Day 85","description":"Maximum change in recorded FEV1 value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.293","spread":"0.008"},{"groupId":"OG001","value":"0.290","spread":"0.008"},{"groupId":"OG002","value":"0.225","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Therapeutic FEV1 Response at Day 1","description":"Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 1","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":"NA"},{"groupId":"OG001","value":"12","spread":"NA"},{"groupId":"OG002","value":"28","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Therapeutic FEV1 Response at Day 29","description":"Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 29","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":"NA"},{"groupId":"OG001","value":"13","spread":"NA"},{"groupId":"OG002","value":"27","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Therapeutic FEV1 Response at Day 57","description":"Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 57","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":"NA"},{"groupId":"OG001","value":"12","spread":"NA"},{"groupId":"OG002","value":"29","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Therapeutic FEV1 Response at Day 85","description":"Achievement of recorded FEV1 measurement of at least 1.15 times of the corresponding test-day baseline value at any time during the first 2 hours of observation after drug administration at Day 85","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":"NA"},{"groupId":"OG001","value":"13","spread":"NA"},{"groupId":"OG002","value":"27","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Duration of Therapeutic FEV1 Response at Day 1","description":"The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 1","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":"NA"},{"groupId":"OG001","value":"219","spread":"NA"},{"groupId":"OG002","value":"104","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Duration of Therapeutic FEV1 Response at Day 29","description":"The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 29","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":"NA"},{"groupId":"OG001","value":"178","spread":"NA"},{"groupId":"OG002","value":"122","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Duration of Therapeutic FEV1 Response at Day 57","description":"The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 57","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":"NA"},{"groupId":"OG001","value":"194","spread":"NA"},{"groupId":"OG002","value":"84","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Duration of Therapeutic FEV1 Response at Day 85","description":"The time interval between the onset and the the termination of a therapeutic FEV1 response (at least 1.15 times the corresponding test-day baseline value) during the 6-hour observation period at Day 85","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":"NA"},{"groupId":"OG001","value":"172","spread":"NA"},{"groupId":"OG002","value":"70","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Peak FEV1 Response at Day 1","description":"The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 1","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"NA"},{"groupId":"OG001","value":"60","spread":"NA"},{"groupId":"OG002","value":"120","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Peak FEV1 Response at Day 29","description":"The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 29","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"NA"},{"groupId":"OG001","value":"60","spread":"NA"},{"groupId":"OG002","value":"120","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Peak FEV1 Response at Day 57","description":"The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 57","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"NA"},{"groupId":"OG001","value":"60","spread":"NA"},{"groupId":"OG002","value":"60","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time to Peak FEV1 Response at Day 85","description":"The first time point at which the maximum change in recorded FEV1 data from the corresponding test-day baseline occurred during the 6-hours observation period after drug administration at Day 85","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":"NA"},{"groupId":"OG001","value":"60","spread":"NA"},{"groupId":"OG002","value":"60","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-6 at Day 1","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.337","spread":"0.015"},{"groupId":"OG001","value":"0.354","spread":"0.015"},{"groupId":"OG002","value":"0.25","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-6 at Day 29","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.015"},{"groupId":"OG001","value":"0.319","spread":"0.015"},{"groupId":"OG002","value":"0.246","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-6 at Day 57","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":"0.015"},{"groupId":"OG001","value":"0.303","spread":"0.015"},{"groupId":"OG002","value":"0.22","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-6 at Day 85","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 6 hours divided by 6 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.279","spread":"0.015"},{"groupId":"OG001","value":"0.283","spread":"0.015"},{"groupId":"OG002","value":"0.219","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-4 at Day 1","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.408","spread":"0.016"},{"groupId":"OG001","value":"0.422","spread":"0.016"},{"groupId":"OG002","value":"0.297","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-4 at Day 29","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.381","spread":"0.015"},{"groupId":"OG001","value":"0.388","spread":"0.015"},{"groupId":"OG002","value":"0.291","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-4 at Day 57","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.361","spread":"0.015"},{"groupId":"OG001","value":"0.380","spread":"0.015"},{"groupId":"OG002","value":"0.264","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC0-4 at Day 85","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 0 to 4 hours divided by 4 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.359","spread":"0.015"},{"groupId":"OG001","value":"0.359","spread":"0.015"},{"groupId":"OG002","value":"0.265","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC4-6 at Day 1","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.017"},{"groupId":"OG001","value":"0.221","spread":"0.017"},{"groupId":"OG002","value":"0.156","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"FVC AUC4-6 at Day 29","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.137","spread":"0.017"},{"groupId":"OG001","value":"0.180","spread":"0.017"},{"groupId":"OG002","value":"0.156","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"FVC AUC4-6 at Day 57","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.128","spread":"0.016"},{"groupId":"OG001","value":"0.147","spread":"0.016"},{"groupId":"OG002","value":"0.13","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"FVC AUC4-6 at Day 85","description":"Area between the test-day baseline FVC and the FVC change from the test-day baseline curve from 4 to 6 hours divided by 2 at Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.117","spread":"0.017"},{"groupId":"OG001","value":"0.130","spread":"0.017"},{"groupId":"OG002","value":"0.124","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 1","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.017"},{"groupId":"OG001","value":"0.612","spread":"0.017"},{"groupId":"OG002","value":"0.479","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 29","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.594","spread":"0.017"},{"groupId":"OG001","value":"0.591","spread":"0.017"},{"groupId":"OG002","value":"0.465","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 57","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.562","spread":"0.017"},{"groupId":"OG001","value":"0.577","spread":"0.017"},{"groupId":"OG002","value":"0.445","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 85","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.575","spread":"0.017"},{"groupId":"OG001","value":"0.562","spread":"0.017"},{"groupId":"OG002","value":"0.449","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 1","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.017"},{"groupId":"OG001","value":"0.612","spread":"0.017"},{"groupId":"OG002","value":"0.479","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 29","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 29","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.594","spread":"0.017"},{"groupId":"OG001","value":"0.591","spread":"0.017"},{"groupId":"OG002","value":"0.465","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 57","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 57","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.562","spread":"0.017"},{"groupId":"OG001","value":"0.577","spread":"0.017"},{"groupId":"OG002","value":"0.445","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Peak FVC Response at Day 85","description":"Maximum change in recorded FVC value from the corresponding test-day baseline within the first 2 hours after drug administration on Day 85","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.575","spread":"0.017"},{"groupId":"OG001","value":"0.562","spread":"0.017"},{"groupId":"OG002","value":"0.449","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Use on Pulmonary Test Day 1","description":"Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 1","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Use on Pulmonary Test Day 29","description":"Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 29","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Use on Pulmonary Test Day 57","description":"Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 57","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Rescue Medication Use on Pulmonary Test Day 85","description":"Number of patients used rescue medication during the 6-hour pulmonary function testing after drug administration on Day 85","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Night-time Rescue Medication Use","description":"The mean number of puffs of rescue medication used during the night-time per week during the entire study (including baseline and on-treatment period)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.977","spread":"0.047"},{"groupId":"OG001","value":"0.977","spread":"0.047"},{"groupId":"OG002","value":"0.997","spread":"0.048"}]}]}]},{"type":"SECONDARY","title":"Daytime Rescue Medication Use","description":"The mean number of puffs of rescue medication used during the daytime per week during the entire study (including baseline and on-treatment period)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.089"},{"groupId":"OG001","value":"2.191","spread":"0.089"},{"groupId":"OG002","value":"2.456","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Night-time Symptom Score","description":"The weekly mean night-time symptom score per week during the entire study (including baseline and on-treatment period).\n\nNight-time COPD symptoms: 0=none 1=some - slept well 2=woke once 3=woke several times 4=woke most of night","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.922","spread":"0.023"},{"groupId":"OG001","value":"0.914","spread":"0.024"},{"groupId":"OG002","value":"0.857","spread":"0.024"}]}]}]},{"type":"SECONDARY","title":"Daytime Symptom Score","description":"The weekly mean daytime symptom score per week during the entire study (including baseline and on-treatment period).\n\nDaytime COPD symptoms: 0=none 1=occasional 2=frequent, no interference with activities 3=most of day, interference with activities 4=prevent working and activities","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.015","spread":"0.022"},{"groupId":"OG001","value":"1.002","spread":"0.022"},{"groupId":"OG002","value":"0.999","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"Trough Peak Expiratory Flow Rate (PEFR)","description":"The weekly mean trough PEFR during the entire study (including baseline and on-treatment period)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.95","spread":"1.51"},{"groupId":"OG001","value":"190.290","spread":"1.526"},{"groupId":"OG002","value":"189.51","spread":"1.551"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation Score on Pulmonary Function Testing Day 29","description":"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.\n\nScore: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.936","spread":"0.041"},{"groupId":"OG001","value":"4.859","spread":"0.041"},{"groupId":"OG002","value":"4.99","spread":"0.041"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation Score on Pulmonary Function Testing Day 57","description":"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.\n\nScore: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.971","spread":"0.045"},{"groupId":"OG001","value":"4.965","spread":"0.045"},{"groupId":"OG002","value":"5.04","spread":"0.046"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation Score on Pulmonary Function Testing Day 85","description":"Physician's Global Evaluation score is based on the need for concomitant medication, number and severity of exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, etc.\n\nScore: 1,2 = poor; 3,4 = fair; 5,6 =good; 7,8 = excellent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.115","spread":"0.048"},{"groupId":"OG001","value":"5.018","spread":"0.048"},{"groupId":"OG002","value":"5.097","spread":"0.048"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the On-treatment Period","description":"COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":null},{"groupId":"OG001","value":"13.03","spread":null},{"groupId":"OG002","value":"10.35","spread":null}]}]}]},{"type":"SECONDARY","title":"COPD Exacerbation Rate During the On-treatment Period","description":"Proportion of patients experiencing a COPD exacerbation per patient year. COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"NA"},{"groupId":"OG001","value":"0.69","spread":"NA"},{"groupId":"OG002","value":"0.53","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"COPD Exacerbation During the On-treatment Period","description":"COPD exacerbation is defined as an increase or new onset of more than one of the following respiratory symptoms (cough, sputum, sputum purulence, wheezing, dyspnea, and chest tightness) having a duration of three or more days requiring treatment with an antibiotic and/or systemic steroids with or without hospital admission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":null},{"groupId":"OG001","value":"2.93","spread":null},{"groupId":"OG002","value":"2.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency Distribution of Satisfaction Rating With Inhaler Attributes","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"351","spread":null},{"groupId":"OG001","value":"305","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"407","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Overall Feeling of Inhaling Medicine","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.411","spread":"0.049"},{"groupId":"OG001","value":"5.810","spread":"0.049"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Feeling That the Inhaled Dose Goes to the Lung","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.326","spread":"0.049"},{"groupId":"OG001","value":"5.808","spread":"0.049"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Telling the Amount of Medication Left","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.573","spread":"0.057"},{"groupId":"OG001","value":"6.184","spread":"0.057"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - The Inhaler Works Reliably","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.682","spread":"0.044"},{"groupId":"OG001","value":"6.190","spread":"0.044"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Ease of Inhaling a Dose From the Inhaler","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.729","spread":"0.046"},{"groupId":"OG001","value":"6.150","spread":"0.046"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Instructions for Use","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.048","spread":"0.036"},{"groupId":"OG001","value":"6.275","spread":"0.036"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - The Inhaler is Durable","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.014","spread":"0.037"},{"groupId":"OG001","value":"6.279","spread":"0.037"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Using the Inhaler","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.749","spread":"0.045"},{"groupId":"OG001","value":"6.127","spread":"0.045"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Speed of Medicine Coming Out of the Inhaler","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.715","spread":"0.047"},{"groupId":"OG001","value":"6.117","spread":"0.047"}]}]}]},{"type":"SECONDARY","title":"Mean Rating Scores of Satisfaction With Inhaler - Overall Satisfaction With Inhaler","description":"Patients rated their response on a seven point Likert scale:\n\n1 = very dissatisfied, 2 = dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = satisfied, 7 = very satisfied.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.639","spread":"0.048"},{"groupId":"OG001","value":"6.103","spread":"0.048"}]}]}]},{"type":"SECONDARY","title":"Device Preference (Respimat or MDI)","description":"Frequency of patients due to device preference","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"584","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]}]},{"type":"SECONDARY","title":"Rating of Action of Turning Clear Base of Respimat","description":"Frequency of patients due to rating of action of turning clear base of Respimat","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"587","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Noncompartmental Pharmacokinetic Parameters of Ipratropium at Steady State","description":"Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCÏ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":"55.4"},{"groupId":"OG001","value":"123","spread":"79.3"},{"groupId":"OG002","value":"115","spread":"50.9"}]}]}]},{"type":"SECONDARY","title":"Noncompartmental Parameters of Albuterol at Steady State","description":"Geometric mean area under the plasma drug concentration time curve over one dosing interval (AUCÏ). Each patient had eight plasma samples (trough pre-dose, 5, 15, 30, and 60 minutes post-dose, as well as 2, 4, and 6 hours post-dose).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"74.3"},{"groupId":"OG001","value":"5.52","spread":"61.4"}]}]}]},{"type":"SECONDARY","title":"Cumulative Amounts of Ipratropium [Î¼g] Excreted in Urine for 0-2 Hours","description":"Cumulative amounts of Ipratropium \\[Î¼g\\] excreted in urine - Planned time intervals 0-2, ss","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.747","spread":"148"},{"groupId":"OG001","value":"0.692","spread":"180"},{"groupId":"OG002","value":"0.723","spread":"220"}]}]}]},{"type":"SECONDARY","title":"Cumulative Amounts of Albuterol [Î¼g] Excreted in Urine for 0-2 Hours","description":"Cumulative amounts of Albuterol \\[Î¼g\\] excreted in urine - Planned time intervals 0-2,ss.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"143"},{"groupId":"OG001","value":"20.3","spread":"141"}]}]}]},{"type":"SECONDARY","title":"Cumulative Amounts of Ipratropium [Î¼g] Excreted in Urine for 0-6 Hours","description":"Cumulative amounts of Ipratropium \\[Î¼g\\] excreted in urine - Planned time intervals 0-6,ss","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"128"},{"groupId":"OG001","value":"1.41","spread":"143"},{"groupId":"OG002","value":"1.51","spread":"145"}]}]}]},{"type":"SECONDARY","title":"Cumulative Amounts of Albuterol [Î¼g] Excreted in Urine for 0-6 Hours","description":"Cumulative amounts of Albuterol \\[Î¼g\\] excreted in urine - Planned time intervals 0-6, ss","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"123"},{"groupId":"OG001","value":"39.4","spread":"116"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17},"commonTop":["Chronic obstructive pulmonary disease"]}}}